BLEOMYCIN-INDUCED INTERSTITIAL PNEUMONITIS AND PNEUMOMEDIASTINUM: CASE STUDY
Main Article Content
Abstract
Bleomycin, a Glycopeptide antibiotic, was discovered in 1966 to possess antitumor cytotoxic activity. Its potent tumoricidal properties have secured it a vital role in cancer chemotherapy. While it causes minimal myelosuppression, pulmonary toxicity is a serious and potentially life-threatening adverse effect, occurring in approximately 10% of patients (range 6-18%), with a reported mortality rate of 3-5%. The patterns of lung injury are diverse and include diffuse alveolar damage (DAD), interstitial fibrosis, nonspecific interstitial pneumonia (NSIP), organizing pneumonia (OP), and eosinophilic pneumonia. Pneumothorax and pneumomediastinum are recognized as very rare complications of Bleomycin. Herein, we present a rare case of Bleomycin-induced interstitial pneumonia complicated by spontaneous pneumomediastinum. This case highlights the importance of early recognition, accurate differential diagnosis, and prompt management of this uncommon yet potentially fatal complication.
Article Details
Keywords
Interstitial pneumonia, mediastinal emphysema, drug-induced lung disease, Bleomycin-induced lung disease.
References
[2] Balaji O, Amita D, Patil N, Thomas J. Bleomycin-induced reversible acute interstitial pneumonia. Asian J Pharm Clin Res, 2017, 10 (5): 6-8. doi: 10.22159/ajpcr.2017.v10i5.17121
[3] O’Sullivan J.M, Huddart R.A, Norman A.R, Nicholls J, Dearnaley D.P, Horwich A. Predicting the risk of Bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol Off J Eur Soc Med Oncol, 2003, 14 (1): 91-96. doi: 10.1093/annonc/mdg020
[4] Uzel I, Ozguroglu M, Uzel B et al. Delayed onset Bleomycin -induced pneumonitis. Urology, 2005, 66 (1): 195. doi: 10.1016/j.urology.2005.01.038
[5] Spagnolo P, Bonniaud P, Rossi G, Sverzellati N, Cottin V. Drug-induced interstitial lung disease. European Respiratory Journal, 2022, 60 (4): 2102776. doi: 10.1183/13993003.02776-2021
[6] Sleijfer S. Bleomycin-induced pneumonitis. Chest, 2001, 120 (2): 617-624. doi: 10.1378/chest.120.2.617
[7] Hay J, Shahzeidi S, Laurent G. Mechanisms of Bleomycin -induced lung damage. Arch Toxicol, 1991, 65 (2): 81-94. doi: 10.1007/BF02034932
[8] Lauritsen J, Kier M.G.G, Bandak M et al. Pulmonary function in patients with germ cell cancer treated with Bleomycin, Etoposide, and Cisplatin. J Clin Oncol Off J Am Soc Clin Oncol, 2016, 34 (13): 1492-1499. doi: 10.1200/JCO.2015.64.8451
[9] Grahmann P.R, Brauer M, Hüter L, Sayer H, Neumann R, Braun R.K. Respiratory failure and pulmonary fibrosis as a late side-effect after chemotherapy-induced by oxygen administration. Pneumol Stuttg Ger, 2005, 59 (11): 763-769. doi: 10.1055/s-2005-919069
[10] Bijawat K, Yumori C et al. Bleomycin-induced pneumonitis (BIP) complicated by large-volume pneumomediastinum. Am J Respir Crit Care Med, 2025, 211 (Supplement_1): A1894. doi: 10.1164/ajrccm.2025.211.
[11] Iteen A.J, Bianchi W, Sharman T. Pneumomediastinum. StatPearls. NCBI Bookshelf. Accessed September 30, 2025.
[12] Sahni S, Verma S, Grullon J, Esquire A, Patel P, Talwar A. Spontaneous pneumomediastinum: time for consensus. North Am J Med Sci, 2013, 5 (8): 460-464. doi: 10.4103/1947-2714.117296